Peptide Reference
PT-141
Bremelanotide
A melanocortin receptor agonist and synthetic analog of alpha-MSH. FDA-approved for premenopausal women with hypoactive sexual desire disorder (HSDD).
Status
approved
Category
sexual health
Typical cost
$600-1000/month
Mechanism
Activates melanocortin receptors (MC1R, MC3R, MC4R) in the central nervous system, increasing sexual arousal and desire through central mechanisms rather than peripheral blood flow.
Potential benefits
- Increased sexual desire
- Enhanced arousal
- Works in women with HSDD
- On-demand dosing
- Non-hormonal mechanism
- FDA-approved
- Works in 45 minutes
- Non-hormonal
- Central arousal mechanism
- Both sexes respond
Reported side effects
- Nausea (40%)
- Vomiting
- Flushing
- Injection site reactions
- Headache
- Blood pressure elevation
- Facial flushing
- Injection reactions
Common dosing references
subcutaneous
1.75mg · As needed (45 min before activity)
Max 8 doses/month
subcutaneous
1.75mg · As needed (45 min before)
PRN, max 8x/month
subcutaneous (research)
500-1500mcg · Daily
8-16 weeks
Research notes
Bremelanotide phase III trials
2019
FDA approval based on significant improvement in sexual desire and reduced distress in premenopausal women
PT-141 RECONNECT trials
2019
Significant improvements in sexual desire in women with HSDD
PT-141 in men
2008
Demonstrated efficacy for erectile dysfunction before focus shifted to women
Regulatory and sourcing notes
FDA-approved (Vyleesi) for premenopausal women with HSDD. Not approved for men or postmenopausal women. Prescription required.
Prescription only (Vyleesi). Auto-injector device. Limited to 8 doses per month due to side effects.
Find peptide-aware clinics
Use location pages to compare clinics with peptide therapy signals and verify clinical oversight before treatment.
Related peptides